news
EMA recommends authorisation for remdesivir to combat COVID-19
The EMA's human medicines committee (CHMP) has recommended a conditional marketing authorisation for Veklury (remdesivir) to treat COVID-19.
List view / Grid view
Viruses
article
Collaborating in the fight against COVID-19
The founder of Apple Steve Jobs once said, “Great things in business are never done by one person; they’re done by a team of people.” This is true now more than ever as medical device manufacturers and companies from a range of industries work together in the fight against COVID-19.…
news
Over 2,000 clinical trials currently underway for COVID-19 therapies, finds study
New findings have revealed that over 2,000 clinical trials are being conducted to test COVID-19 therapies while 583 companies are involved in treatment and vaccine development.
news
First patient dosed with COVID-19 vaccine using self-amplifying RNA
A Phase I clinical trial to test Imperial College London's COVID-19 vaccine candidate has been initiated, with the first patient dosed.
news
Consortium established to monitor COVID-19 vaccines after marketing
A new consortium has been formed for the study of COVID-19 vaccines after their approval, to monitor their safety and efficacy.
news
Ruxolitinib to be studied as COVID-19 treatment in clinical trial
Following the successful treatment of a COVID-19 patient with ARDS using ruxolitinib, Germany is set to begin clinical trials to test the drug.
news
Glenmark approved to supply favipiravir as COVID-19 treatment in India
Indian authorities have given their first approval for the oral antiviral favipiravir for treatment of COVID-19 to Glenmark Pharmaceuticals.
article
Bioprocessing & Bioproduction In-Depth Focus 2020
This in-depth focus includes articles detailing five important considerations for European companies entering the US biosimilar market and explaining why virally vectored DNA and mRNA vaccines could prevent the spread of COVID-19.
article
European Pharmaceutical Review Issue 3 2020
In this issue is a discussion on the promise of virally vectored DNA and mRNA vaccines to combat COVID-19 as well as articles on how packaging could help to ensure patient adherence, regulatory issues for medicines and diagnostics during the pandemic and the benefits of digitalising the pharmaceutical supply chain.…
news
Dexamethasone to be available on NHS as COVID-19 treatment
The UK government has approved dexamethasone to be available on the NHS, following clinical trials proving its efficacy at reducing the risk of death for COVID-19 patients.
news
Clinical trial disruption from COVID-19 beginning to lessen, says report
New findings reveal that the 200 clinical trials impacted and delayed by COVID-19 are now continuing or have completed their course.
news
AstraZeneca commits to supply Europe with 400 million doses of COVID-19 vaccine candidate
AstraZeneca plans to produce up to 400 million doses of the University of Oxford’s COVID-19 vaccine candidate, with deliveries to begin by the end of the year.
news
Lilly enrols first COVID-19 patient in Phase III study to test baricitinib
A Phase III trial has been launched to study whether baricitinib, an oral JAK1/JAK2 inhibitor, is effective at combatting COVID-19 in hospitalised patients.
news
EDQM to provide COVID-19 vaccine developers free access to quality standards
The EDQM and European Pharmacopoeia have decided to share Ph. Eur. quality standards for COVID-19 vaccine developers to support their research.
news
Dexamethasone could reduce COVID-19 patient death risk by one-third, study shows
A clinical trial has shown that an inexpensive steroid called dexamethasone could prevent death in one out of eight ventilated COVID-19 patients and one out of 25 patients receiving oxygen only.
